Redcare Revenue Surges 25% as Customer Base Grows by 200,000
Redcare, the pharmaceutical giant, has reported a surge in revenue and customer base, driving its share price up by 19 percent. The company's success is attributed to targeted marketing campaigns and further growth is expected.
Redcare's prescription medication revenue in Germany soared by 82 percent to 126 million euros. This impressive growth is part of a broader trend, with German Rx revenue surging 122 percent to 348 million euros over the first nine months of 2025. The company's total revenue climbed 25.2 percent to 719 million euros, driven by solid growth in all segments.
Redcare's customer base has also grown significantly, now standing at 13.7 million active customers, an increase of 200,000 from the previous quarter. The company's share price jumped up to 19 percent due to these strong quarterly figures. Jefferies, an analyst, attributes this success to targeted marketing campaigns and sees further growth drivers on the horizon.
The sequential quarterly growth of 12 million euros in prescription medication revenue marks a significant acceleration. Redcare confirmed all annual targets, including more than 25 percent revenue growth and an EBITDA margin between 2 and 2.5 percent. The non-Rx area, over-the-counter products, also grew by nearly 17 percent. International expansion contributed to a 25.4 percent revenue growth in Belgium, Italy, France, and the Netherlands.
Redcare's impressive financial performance, driven by growth in both prescription and over-the-counter products, along with international expansion, has positioned the company for continued success. Despite the sudden price drops in October 2022, the company has rebounded strongly and is on track to meet its annual targets.
